<table>
<thead>
<tr>
<th>Title</th>
<th>Sirt1 plays an important role in mediating greater functionality of human ES/iPS-derived vascular endothelial cells.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Homma, Koichiro; Sone, Masakatsu; Taura, Daisuke; Yamahara, Kenichi; Suzuki, Yutaka; Takahashi, Kazutoshi; Sonoyama, Takuhiro; Inuzuka, Megumi; Fukunaga, Yasutomo; Tamura, Naohisa; Itoh, Hiroshi; Yamanaka, Shinya; Nakao, Kazuwa</td>
</tr>
<tr>
<td>Citation</td>
<td>Atherosclerosis (2010), 212(1): 42-47</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2010-09</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/2433/130711">http://hdl.handle.net/2433/130711</a></td>
</tr>
<tr>
<td>Right</td>
<td>© 2010 Published by Elsevier Ltd; この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.</td>
</tr>
<tr>
<td>Type</td>
<td>Journal Article</td>
</tr>
<tr>
<td>Textversion</td>
<td>author</td>
</tr>
</tbody>
</table>

Kyoto University
Sirt1 plays an important role in mediating greater functionality of human ES/iPS derived vascular endothelial cells

Koichiro Homma\textsuperscript{a,e}, Masakatsu Sone\textsuperscript{a}, Daisuke Taura\textsuperscript{a}, Kenichi Yamahara\textsuperscript{a}, Yutaka Suzuki\textsuperscript{b}, Kazutoshi Takahashi\textsuperscript{c,d}, Takuhiro Sonoyama\textsuperscript{a}, Megumi Inuzuka\textsuperscript{a}, Yasutomo Fukunaga\textsuperscript{a}, Naohisa Tamura\textsuperscript{a}, Hiroshi Itoh\textsuperscript{e}, Shinya Yamanaka\textsuperscript{c,d}, Kazuwa Nakao\textsuperscript{a}

\textsuperscript{a}Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine, Kyoto, Japan

\textsuperscript{b}Stem Cell and Drug Discovery Institute, Kyoto, Japan

\textsuperscript{c}Department of Stem Cell Biology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan

\textsuperscript{d}Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell-Material Sciences, Kyoto, Japan

\textsuperscript{e}Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

\textsuperscript{*Correspondence to:}

Masakatsu Sone, MD, PhD

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
Tel: +81-75-751-3170

Fax: +81-75-771-9452

E-mail: sonemasa@kuhp.kyoto-u.ac.jp

Total word count of the manuscript: 3938 words
Abstract

Objective  We previously succeeded in inducing and isolating vascular endothelial cells (ECs) from both human embryonic stem (ES) and induced pluripotent stem (iPS) cells. Here, we compared the functionality of human adult ECs (HAECs), human ES-derived ECs (ESECs) and human iPS-derived ECs (iPSECs).

Methods and Results  We compared the cell proliferative potential, potential for migration, and tolerance to oxidative stress. ESECs were significantly superior to HAECs in all of these cell functions. The cell functions of iPSECs were comparable to those of ESECs and also superior to HAECs. We then analyzed the gene expressions of HAECs, ESECs and iPSECs, and observed that the expression level of Sirt1, a nicotinamide adenine dinucleotide (NAD+)-dependent histone deacetylase, is higher in ESECs and iPSECs than in HAECs. The inhibition of Sirt1 with a Sirt1-specific inhibitor and siRNA antagonized these differences between the three types of cells.

Conclusions  Sirt1 plays a key role in the high cellular function of ESECs and iPSECs. Although further in vivo investigations are required, this study initially demonstrated the potential of ESECs and iPSECs as the cell source for regenerative medicine, and also showed the potential of ES cells as a useful tool for elucidating the molecular mechanism of cell aging.

Key words

Stem cells, endothelium, Sirt1
Introduction

We have succeeded in selectively inducing mouse, monkey and human ES cells to differentiate into ECs and mural cells and in isolating those cells (1-3). In addition, we recently succeeded in inducing human iPS cells to differentiate into ECs and mural cells and in isolating those cells (4). We have also intra-arterially transplanted human ES cell-derived ECs (ESECs) into murine hindlimb ischemia models and found that the transplanted ECs are incorporated into the host vasculature, where they promote the restoration of blood flow. By contrast, almost no transplanted adult aorta-derived ECs were incorporated into the host vasculature, and they did not promote blood flow restoration (3, 5). Other groups comparing the efficiency of engraftment of ESECs and human adult ECs obtained similar results (6-8). Apparently, there are functional differences between ESECs, which are at a relatively early stage of development, and human adult ECs, which have already been subject to aging.

The aims of the present study were to analyze the functional differences between human adult ECs, ESECs and human iPS cells-derived ECs (iPSECs), to identify factors responsible for these functional differences, and to determine at least part of the mechanism of vascular aging.
Methods

Cell culture

Human aortic endothelial cells (HAECs) were purchased from Lonza and maintained in endothelial growth medium (EGM-2, EGM-2 singleQuots, Lonza). Human saphenous vein endothelial cells (HVECs) were purchased from VEC Technologies, Inc., and maintained in EGM-2 (EGM-2 singleQuots). The khES1 human ES cell line and the 201B7 human iPS cell line were used and maintained as described previously (4). Briefly, every 5 to 6 days, undifferentiated cells of both cell lines were detached with dissecting pipettes and transferred to dishes with mitomycin C-treated mouse feeder cells. All endothelial cells used in this study were not passaged more than five times.

Induction of differentiation

Undifferentiated human ES or iPS cells were harvested and transferred to a collagen I-coated dish after adjusting the colonies to an appropriate size. On the second day of incubation, the culture medium was replaced with human ES/iPS cell maintenance medium without basic FGF, supplemented with N2 supplement (Invitrogen)/B27 supplement (Invitrogen) and BIO (SIGMA). Thereafter, the cells were incubated for another 3 days, at which time the culture medium was replaced with StemPro-34 SFM (Invitrogen) supplemented with VEGF (50 ng/ml; PeproTech EC Ltd). After another 3-5 days of incubation, Flk1/VE-cadherin+/+ cells were sorted using FACSaria flow cytometer and used for the following experiments. Sorted cells were confirmed to remain VE-cadherin positive during the following cell culture and analyses.

Immunohistochemistry

Cultured cells were stained with an anti-VE-cadherin antibody (BV-9, Abcam) (9), or the indicated monoclonal antibodies as described (4).
MTT assay

Cell proliferation was assessed in colorimetric 3,4,5-dimethylthiazol-2-yl-2,5-diphenyl tetrazolium bromide (MTT) assays carried out as described previously (10). Briefly, cells were incubated with MTT (Nakarai Tesque, Kyoto, Japan) solution for 4 h, after which the medium was discarded. The remaining dye was then dissolved in dimethyl sulfoxide, and the absorbance was measured at 570 nm.

In vitro wound healing assay

Wound healing assays were carried out as we described previously (11). Briefly, ECs were grown to overconfluence in six-well plates, after which a wound approximately 2 mm in width was made with a cell scraper. The wound was then allowed to heal (re-endothelialize) for 24 h in the same medium. The wounded monolayer was photographed before and after the incubation period, and the area of re-endothelialization was evaluated.

Annexin V assay

Confluent monolayers (80-90%) of ECs grown in 6-well plates were treated with or without 300 μmol/l H$_2$O$_2$. After 8 h of exposure, annexin V-FITC in combination with Via-Probe was used to quantitatively determine the percentage of cells undergoing apoptosis, as described previously (12). Briefly, after treating the cells with the indicated reagents, the monolayer was detached by a brief incubation with Trypsin–EDTA solution. Aliquots of cells (10$^5$) were then resuspended in 1x binding buffer (BD Pharmingen, San Diego, CA) and incubated with annexin V-FITC for 15 min at room temperature in the dark, stained with Via-Probe, and analyzed within 1 h in a FACSARia flow cytometer. FACS Diva software (Becton Dickinson) was used to analyze the data. Early apoptotic cells were stained with annexin V only, while late apoptotic or necrotic cells were stained with both annexin V and Via-Probe.
Quantitative real-time PCR

Total RNA was isolated using an RNeasy\textsuperscript{\textregistered} Mini Kit and treated with an RNase-Free DNase Set (QIAGEN, Germany) to remove any contaminating genomic DNA. Quantitative real-time PCR was then performed using Premix ExTaq\textsuperscript{\textregistered}M (Takara Bio Inc., Shiga, Japan). The PCR primers used were as follows: for Sirt1, GCCTCACATGCAAGCTCTAGTGAC (forward) and TTGGAGATCTGTGCCAATCATAA (reverse); for Delta-like 4 (DLL4), GTGGACTGTGGGCTGGACAA (forward) and AGCATATCGCTGATATCCGACACACTC (reverse); for CXCR4, GCCAACGTAGTCAGTGAGGCAGA (forward) and GCCAACCATGATGTGCTGAAAC (reverse) and for β-actin, CATCCGTAAAGACCTCTATGCCAC (forward) and ATGGAGCCACCATCCACA (reverse). All primers were produced by Takara Bio. Levels of Sirt1, DLL4 and CXCR4 mRNA are presented after normalization to the level of β-actin mRNA.

Western blot analysis

Western blotting was carried out using a standard protocol described previously (13). Anti-Sirt1 antibody was purchased from Santa Cruz Biotechnology, Inc.

siRNA transfection

Small interference RNA (siRNA) against Sirt1 and negative control were provided by Qiagen. The target sequence for the Sirt1 siRNA was 5’CAA GCG ATG TTT GAT ATT GAA3’. ECs were trypsinized, washed with Hank’s Balanced Salt Solution, resuspended (5×10\textsuperscript{5} cells) in human umbilical vein endothelial cell solution (Amixa Biosystems) containing 3 μg of siRNA duplex, and then transfected using a Nucleofector (Amixa Biosystems) following the manufacturer’s instructions. After transfection, the cells were immediately plated in dishes.

Endothelial tube formation assay
Endothelial tube formation was assayed as described previously (14). ECs (20,000 cells/well) were seeded into Matrigel-coated 24-well plates. The cells were then incubated for 12 h at 37°C, after which the formed tubes were digitally imaged and analyzed using MetaMorph software (Universal Imaging Corp.).

Statistical analysis.

Results are presented as means±SEM. Differences between groups were analyzed using ANOVA followed by Fisher’s analysis for comparisons between two means. Values of $P < 0.05$ were considered significant.

Results

Morphological comparison of HAECs, ESECs and iPSECs

HAECs, ESECs and iPSECs were morphologically similar in that they all exhibited a cobblestone-like appearance on culture dishes, were positive for eNOS, and showed a marginal staining pattern when stained for CD31 and VE-cadherin (Figure 1). All of these features are characteristic of vascular endothelial cells. Furthermore, HVECs, an example of venous endothelial cells, were analyzed together with HAECs, ESECs and iPSECs by real-time PCR for the expression of arterial endothelial marker genes, DLL4 and CXCR4. The expression levels of DLL4 and CXCR4 in both ESECs and iPSECs were comparable with those in HAECs and higher than those in HVECs (supplementary Figure I), suggesting that both ESECs and iPSECs are near artery-lineage.

Comparison of the potentials for proliferation and migration and tolerance for oxidative stress of HAECs, ESECs and iPSECs

MTT assays carried out to evaluate their proliferative potential revealed ESECs and iPSECs to have a significantly greater potential for proliferation than HAECs, but there was no significant
difference between ESECs and iPSECs (Figure 2A). Similarly, an in vitro wound healing assay revealed that ESECs and iPSECs to have a significantly higher potential for migration after EC loss than HAECs, and again there was no significant difference between ESECs and iPSECs (Figure 2B). Following induction of oxidative stress by exposure to H₂O₂, moreover, there was a significantly lower percentage of annexin V-positive apoptotic cells among ESECs and iPSECs than among HAECs, with no significant difference between ESECs and iPSECs (Figure 2C).

**Differences in the expression of Sirt1 in HAECs, ESECs and iPSECs**

To identify factors responsible for the functional differences between HAECs, ESECs and iPSECs, we next carried out a gene expression analysis using gene chip technology (supplementary Method, supplementary Figure II). We found that the expression level of Sirt1, an aging-related gene that encodes a NAD-dependent histone deacetylase, was higher in both ESECs and iPSECs than in HAECs. We then confirmed that finding by using real-time PCR to quantitatively compare the levels of Sirt1 mRNA expression in the three cell types. Sirt1 mRNA was expressed at significantly higher levels in both ESECs and iPSECs than in HAECs (Figure 2D), but there was no significant difference in expression between ESECs and iPSECs. Subsequent Western blot analysis of Sirt1 protein expression yielded analogous results (Figure 2E).

**Contribution of Sirt1 to the cellular functionality of HAECs, ESECs and iPSECs**

In view of the possibility that differences in Sirt1 expression contributes to the observed differences in the cellular functionality of HAECs, ESECs and iPSECs, we examined the effects of knocking down Sirt1 expression using siRNA or inhibiting Sirt1 protein using sirtinol (Calbiochem, San Diego, CA), a specific Sirt1 antagonist (15, 16). Using real-time PCR, we found that the targeted siRNA reduced the level of Sirt1 mRNA by about 70%, as compared to the nontargeted siRNA (data not shown). Although under control conditions ESECs and iPSECs showed a significantly greater proliferative potential than HAECs, knocking down Sirt1 expression diminished
proliferation of all three cell types and abolished all differences in proliferative potential (Figure 3A). Likewise, the difference in the cells’ potential for migration also disappeared when Sirt1 was knocked down (Figure 3B). Similar results were obtained when 50 μM sirtinol was applied to the cells (Figure 3A upper, 3B upper). The vehicle control was 0.025% DMSO. Because sirtinol was dissolved in DMSO. On the other hand, differences in tolerance for oxidative stress became nonsignificant, but the trend remained upon Sirt1 knock down (Figure 3C).

Changes in Sirt1 expression level during differentiation towards endothelial cells, and effects of Sirt1 on endothelial cell differentiation

To investigate the involvement of Sirt1 in the differentiation process towards endothelial cells, Sirt1 gene expression level was determined by real-time PCR before and after VEGF stimulation. The level of Sirt1 expression in differentiated mesoblastic cells before VEGF addition was not significantly different from that in the VEGF-stimulated cells immediately before cell sorting (supplementary Figure III A). Furthermore, inhibition of Sirt1 by the addition of 25 mM or 50 mM sirtinol during the induction period did not alter endothelial cell differentiation efficiency (supplementary Figure III B).

Contribution of Sirt1 to the angiogenic activities of HAECs, ESECs and iPSECs

Finally, we used Matrigel assays to determine whether the differences in the functionality of the three cell types are reflected in their angiogenic activities. Consistent with the results summarized above, ESECs and iPSECs showed greater tube formation than HAECs, but that difference was abolished by knocking down Sirt1 expression (Figure 4, supplementary video 1, 2). Similar results were obtained when 50 μM sirtinol was applied to the cells (data not shown).
Discussion

The results of the present study demonstrate that human ESECs have a greater potential for proliferation and migration and a greater tolerance for oxidative stress than HAECs. They also demonstrate that the functionality of iPSECs is similar to that of ESECs.

Gene chip analysis and quantitative comparison using real-time PCR revealed that levels of Sirt1 expression differed between ESECs and HAECs. Sirt1, a mammalian homologue of Sir2, has recently been drawing attention due to its relationship to endothelial function (14-17) and eNOS expression in ECs (18). It has also been reported that Sirt1 is important for the normal function of not only mature endothelial cells but also endothelial progenitor cells (19). All of these previous studies demonstrated a protective role of Sirt1 in endothelial regeneration. In the present study, we found that when Sirt1 activity was knocked down by siRNA or inhibited by a specific Sirt1 antagonist, the aforementioned differences in the cellular functionality of ESECs and HAECs were abolished, which suggests that differences in Sirt1 activity contribute significantly to the observed differences in the cellular functionality of the two cell types. Moreover, this implies that changes in Sirt1 expression play a key role in mediating the effects of aging on human EC function, and that intervention to regulate Sirt1 expression may represent a useful approach to slowing the aging of ECs and improving their functionality.

Cell proliferation and migration are important steps in the process of angiogenesis. Sirt1 was previously shown to promote cell proliferation by suppressing p53 (20) and to promote cell migration through deacetylation of cortactin (21). The differences in their potentials for proliferation and migration are also likely reflected in the results of the in vitro tube formation assays performed to assess the cells’ angiogenic potential. Furthermore, the Matrigel assay showed strongly impaired tube formation due to the suppression of Sirt1 in all three cell types. This suggests that Sirt1 may play an essential role in endothelial sprouting.

The post-transplant engraftment rate is another important indicator of a cell’s utility for transplantation therapy. Several studies have shown that the engraftment rate is closely related to the
incidence of apoptosis induced by inflammatory cytokines produced in inflamed or injured tissues (22). Thus the observed anti-apoptotic effect in ESECs and iPSECs may be indicative of their potential for use in cell transplantation therapy. Nonsignificant but residual differences in tolerance for oxidative stress remained after suppressing Sirt1, suggesting the possible involvement of other factors. The protective effect of Sirt1 against oxidative stress has also been observed by several other studies (15, 16, 23). Balestrieri et al. reported that metabolic intervention enhances therapeutic effects achieved by the administration of bone marrow cells or hemangioblasts alone in a mouse model of hindlimb ischemia (24). In vivo experiments investigating the actual efficacy of a therapy using Sirt1 as a target are anticipated in the future.

The present and previous studies clearly demonstrated that Sirt1 plays an important role in endothelial cell function; however, whether it is involved in endothelial cell differentiation remains unclear. In this study, we showed that Sirt1 expression level was unchanged during induction, and that Sirt1 inhibition during induction did not alter the endothelial cell differentiation efficiency. Therefore, at least in the in vitro induction protocol used in the present study, Sirt1 appeared to have no effect on endothelial cell differentiation.

We found that iPSECs are very similar to ESECs, as judged from their expression of aging-related genes and their cellular functionality. iPSC cells originate from somatic cells and are dedifferentiated through reprogramming. This is noteworthy, as it suggests that cells differentiated from iPS cells (e.g., iPSECs) are relieved of the aging they experienced as somatic cells so that they are functionally as young as cells differentiated from ES cells. This highlights the importance of reprogramming technology and the elucidation of the underlying mechanisms. In addition, in contrast to human ES cells, iPS cells can be established from every human being irrespective of their genetic backgrounds. The establishment of iPS cell lines from patients with inherited diseases presenting vascular abnormality should enable clarification of their pathogenesis. The establishment of iPS cell lines from patients with various genetic backgrounds should make it possible to dissect out cellular mechanisms in human vascular development, aging and diseased states such as
arteriosclerosis.

In conclusion, we have shown that ESECs and iPSECs are younger and more viable than HAECs and are thus potentially useful cellular materials for vascular regeneration. We also showed that the functional differences between ESECs/iPSECs and HAECs is mediated by Sirt1 expression, suggesting Sirt1 plays a pivotal role in aging-associated functional impairment of human ECs.

**Funding**

This work was supported by the project for realization of regenerative medicine of the Ministry of Education, Culture, Sports, Science and Technology, Japan.

**Acknowledgments**

The anti-human Flk1 antibody (KM1668) was a generous gift from Kyowa Hakko Co Ltd. Human ES cell line KhES-1 was obtained from the Institute for Frontier Medical Science, Kyoto University (Kyoto, Japan). This work was supported by the Project for Realization of Regenerative Medicine of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. This work was also supported by Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare, MEXT, the Takeda Science Foundation, the Japan Cardiovascular Research Foundation, and the Smoking Research Foundation. We thank Yoshie Fukuchi and Sonoko Takesue for technical assistance.
References


Figure legends

Figure 1. Phenotypes of HAECs, ESECs and iPSECs.

Typical morphology of an EC monolayer and immunofluorescence staining of the monolayer for CD31, eNOS and VE-cadherin; cell nuclei are stained with DAPI. Scale bar, 100 µm.

Figure 2. Comparison of the potential for proliferation and migration, tolerance for oxidative stress, and Sirt1 expression in HAECs, ESECs and iPSECs.

(A) MTT assay (n=8; *P<0.05)
(B) Wound healing assay (n=4; *P<0.05)
(C) Annexin V assay (n=4-6; *P<0.05)
(D) Quantitative real-time PCR (n=8; *P<0.05)
(E) Western blot analysis (n=4; *P<0.05)

Figure 3. Effects of Sirt1 siRNA or a Sirt1 inhibitor on the potential for proliferation and migration, and tolerance for oxidative stress in HAECs, ESECs and iPSECs.

(A) MTT assay (n=6-8; *P<0.05)
(B) Wound healing assay (n=4; *P<0.05)
(C) Annexin V assay (n=4-6; *P<0.05)

Figure 4. Tube formation by HAECs, ESECs and iPSECs after 12 h of culture on Matrigel.

(A) Representative photomicrographs; scale bar, 100 µm.
(B) Quantitative analysis of tube formation (n=4; *P<0.05)
Figure 1

HAEC

ESEC

iPSEC

morphology  CD31  eNOS  VE-cadherin
Figure 2

A

Cell proliferation activity (OD)

Re-endothelialized area (%)

HAEC  ESEC  iPSEC

0  0.1  0.2  0.3  0.4  0.5

B

SIRT1/β-actin

Expression ratio of SIRT1/β-actin (fold induction over HAEC)

HAEC  ESEC  iPSEC

0  0.05  0.1  0.15  0.2  0.25

C

Annexin V positive cells (%)

HAEC  ESEC  iPSEC

0  5  10  15  20  25  30  35

D

SIRT1

β-actin

Expression ratio of SIRT1/β-actin (fold induction over HAEC)

HAEC  ESEC  iPSEC

0  1  2  3  4  5  6  7

E

Via-Probe
Figure 3

A

Cell proliferation activity (OD)

Re-endothelialized area (%)

nontargeted siRNA
SIRT1 siRNA

ESEC
iPSEC
HAEC

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

ESEC
iPSEC
HAEC

n.s
*

C

Annexin V positive cells (%)

nontargeted siRNA + H₂O₂
Sirt1 siRNA + H₂O₂

n.s
*

n.s
*

n.s
*

n.s
*

n.s
*

n.s
*
Figure 4

**nontargeted siRNA**

**SIRT1 siRNA**

**Number of tube branches/tplf**

<table>
<thead>
<tr>
<th></th>
<th>HAEC</th>
<th>ESEC</th>
<th>iPSEC</th>
<th>HAEC</th>
<th>ESEC</th>
<th>iPSEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>nontargeted siRNA</td>
<td>50±5</td>
<td>60±5</td>
<td>70±5</td>
<td>30±3</td>
<td>40±4</td>
<td>50±5</td>
</tr>
<tr>
<td>SIRT1 siRNA</td>
<td>30±3</td>
<td>40±4</td>
<td>50±5</td>
<td>20±2</td>
<td>30±3</td>
<td>40±4</td>
</tr>
</tbody>
</table>

**Relative percentage of tube length**

<table>
<thead>
<tr>
<th></th>
<th>HAEC</th>
<th>ESEC</th>
<th>iPSEC</th>
<th>HAEC</th>
<th>ESEC</th>
<th>iPSEC</th>
</tr>
</thead>
<tbody>
<tr>
<td>nontargeted siRNA</td>
<td>100±10</td>
<td>110±10</td>
<td>120±10</td>
<td>90±9</td>
<td>100±10</td>
<td>110±10</td>
</tr>
<tr>
<td>SIRT1 siRNA</td>
<td>80±8</td>
<td>90±9</td>
<td>100±10</td>
<td>70±7</td>
<td>80±8</td>
<td>90±9</td>
</tr>
</tbody>
</table>